Abstract :
Prioritizing all placebo-group participants in SARS-CoV-2 vaccine trials as first receivers could perpetuate health inequities and compromise the chance to learn from their participation. Prioritization can be limited to those who would be prioritized for vaccination anyway under National Academies of Science, Engineering and Medicine or Advisory Committee on Immunization Practices frameworks.